Compare CLLS & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management and leasing of diversified and mixed-use properties throughout the United States.